Fig. 9: Evaluation of the effectiveness of antiplatelet drugs in combination with chemotherapy in animal models of CRC. | Cell Death & Disease

Fig. 9: Evaluation of the effectiveness of antiplatelet drugs in combination with chemotherapy in animal models of CRC.

From: Platelet-derived exosomal LINC00183 facilitate colorectal cancer malignant progression driven by histone lactylation through stabilizing ENO1

Fig. 9

A The xenograft nude mouse model’s schematic. B, C A quantitative analysis was conducted on the subcutaneous xenograft model and tumor weight. D Measurement of lactate levels in subcutaneous tumor tissue. E Representative H&E staining, FISH analysis of LINC00183 expression, and CD41 and H3K18la IHC analysis in excised CRC xenografts. F, G RT-qPCR-based quantification of LINC00183 and P2Y12 mRNA in sera from mice bearing CRC xenografts. H and I PET-CT-based assessment of glucose uptake in subcutaneous tumors. J Schematic representation of the chemotherapy/antiplatelet regimens used in the splenic injection model for liver metastasis. K Representative images of bioluminescent in vivo detection of liver metastases. L Total photon flux quantification data. M OS curves. N Representative H&E-staining images, FISH analysis of LINC00183 expression, and CD41 IHC analysis in excised livers. O, P RT-qPCR-based quantification of LINC00183 and P2Y12 mRNA in sera from mice with CRC liver metastases. Q Quantification of lactate levels in excised liver tissue. R Schematic representation of main findings of the current study. LINC00183-induced CRC progression is driven by stabilization of the key glycolytic enzyme ENO1, with consequent H3K18 lactylation and enhanced GDF15 transcription.

Back to article page